加拿大免疫研究网络:RotaTeq两剂次超说明书程序与三剂次批准程序的轮状病毒住院率比较
该准实验研究基于加拿大魁北克、安大略和不列颠哥伦比亚三省2006年9月至2023年3月6–23月龄儿童行政数据库,采用双重差分泊松回归比较魁北克2018年9月实施两剂次RotaTeq程序前后RV-AGE和AGE住院率变化。结果显示两剂次程序未导致RV-AGE住院率显著增加(率比=2.32;95%CI=0.80-6.69),AGE住院率亦无显著变化(率比=1.02;95%CI=0.91-1.14)。
要点
- 魁北克两剂次RotaTeq程序未显著增加6–23月龄儿童RV-AGE住院率。
- 两剂次程序对任何AGE住院率也无显著影响(率比=1.02;95%CI=0.91-1.14)。
- 疫苗程序引入后三省RV-AGE和AGE住院率分别降低87%和56%。
核心结论
- 在高收入、疫苗覆盖率较高的国家,使用两剂次RotaTeq程序未导致轮状病毒相关住院负担显著增加。
- 研究再次证实轮状病毒疫苗接种规划在人群层面具有显著影响。
研究设计与样本
- 准实验研究,时间跨度为2006年9月至2023年3月。
- 主要分析对象为魁北克、安大略和不列颠哥伦比亚三省6–23月龄儿童。
- 数据来自行政数据库,使用诊断特异性ICD-10编码。
- 采用双重差分泊松回归比较魁北克实施两剂次RotaTeq程序前后住院率变化。
主要发现
- 共识别3875例RV-AGE住院和36568例AGE住院。
- 三省疫苗规划引入后RV-AGE和AGE住院率分别降低87%和56%。
- 2018年9月至2020年8月魁北克实施两剂次程序后,三省6–23月龄儿童中仅识别19例RV-AGE住院。
- 魁北克两剂次程序与RV-AGE住院率增加无统计学显著关联(率比=2.32;95%CI=0.80-6.69)。
- 魁北克两剂次程序与AGE住院率无统计学显著关联(率比=1.02;95%CI=0.91-1.14)。
临床怎么用
- 在疫苗覆盖率较高的高收入地区,两剂次RotaTeq程序可作为三剂次程序的可行替代方案。
- 公共卫生决策者可参考本研究结果评估减少轮状病毒疫苗剂次的潜在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rotavirus (RV) vaccination programs were implemented between 2011 and 2012 in Canada and have considerably reduced the burden of RV disease. In September 2018, the province of Quebec implemented a reduced-dose RotaTeq vaccination schedule (two doses). Other provinces, such as British Columbia and Ontario, continued to use the approved three-dose schedule for this product. Our aim was to determine whether using a reduced-dose RotaTeq schedule was associated with an increased burden of RV disease. METHODS: This quasi-experimental study spanned from September 2006 to March 2023. The main analysis focused on children aged 6-23 months in Quebec, Ontario, and British Columbia. Data were retrieved from administrative databases using diagnosis-specific ICD-10 codes. A difference-in-differences approach using Poisson regression was used to compare admission rates for rotavirus-associated acute gastroenteritis (RV-AGE) and for any acute gastroenteritis (AGE) before and after the implementation of a reduced-dose RotaTeq vaccination schedule in Quebec. FINDINGS: A total of 3875 RV-AGE and 36,568 AGE hospital admissions were identified. Across the three provinces, the rates of admission for RV-AGE and AGE were 87% and 56% lower, respectively, after vaccine program introduction as compared to before. After the implementation of the reduced-dose RotaTeq vaccination schedule in Quebec, between September 2018 and August 2020, only 19 RV-AGE hospital admissions were identified among children between 6 and 23 months of age in the three provinces. In Quebec, the reduced schedule was not associated with a statistically significant increase in RV-AGE admissions (rate ratio = 2.32; 95%CI = 0.80-6.69), or for AGE admissions in general (rate ratio = 1.02; 95%CI = 0.91-1.14), compared to temporal trends in the other two provinces. INTERPRETATION: This study provides reassuring evidence regarding the use of a two-dose RotaTeq schedule in a high-income country with relatively high vaccination coverage and reaffirms the substantial impact of RV vaccination introduction at a population level.
引用
- Fortin É, Miron É, Grewal R, et al. Does an off-label two-dose RotaTeq vaccine schedule translate into a higher incidence of rotavirus hospital admissions compared to the approved three-dose RotaTeq schedule? A Canadian immunization research network study. Vaccine. 2026. PMID: 42070371. doi:10.1016/j.vaccine.2026.128628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。